Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of caffeine on dipyridamole-induced protection against ischemia-reperfusion injury
2006-004878-28Phase 4Completed
- Sponsor
- Radboudumc Department of Pharmacology and Toxicology
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dipyridamole in ischemia-reperfusion injury (IRI) and coronary arteriosclerosis (2 arms), sponsored by Radboudumc Department of Pharmacology and Toxicology. Primary endpoints: Percentage difference in radioactivity between experimental and control thenar muscle at 60 minutes after reperfusion and Percentage difference in radioactivity between experimental and control thenar muscle at 240 minutes after reperfusion. Started Jun 2007; status: completed.
02
Drugs
dipyridamole
03
Conditions
ischemia-reperfusion injury (IRI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2006-004878-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004878-28.